Blood plasma is currently being evaluated as a possible treatment for patients with an active COVID-19 infection. LabCorp said it will run the program using individual patients' own doctor. "LabCorp is currently working with public health authorities and the provider community on the details of the three-month program and will provide additional information in the near future," the company said in a statement. Shares were flat in Thursday trade, but have gained 15% in the year to date, while the S&P 500 SPX, -0.56% has gained 0.5%.